Tempus AI, Inc. Class A Common Stock (TEM)vs10X Genomics Inc (TXG)
TEM
Tempus AI, Inc. Class A Common Stock
$47.05
+2.17%
HEALTHCARE · Cap: $7.72B
TXG
10X Genomics Inc
$47.86
+1.81%
HEALTHCARE · Cap: $6.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Tempus AI, Inc. Class A Common Stock generates 114% more annual revenue ($1.36B vs $638.78M). TXG leads profitability with a -3.5% profit margin vs -22.2%. TEM earns a higher WallStSmart Score of 31/100 (F).
TEM
Avoid31
out of 100
Grade: F
TXG
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for TEM.
Margin of Safety
+68.1%
Fair Value
$60.02
Current Price
$47.86
$12.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Trading at 20.3x book value
ROE of -72.7% — below average capital efficiency
Negative free cash flow — burning cash
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : TEM
The strongest argument for TEM centers on Revenue Growth. Revenue growth of 36.1% demonstrates continued momentum.
Bull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bear Case : TEM
The primary concerns for TEM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 3.17 is elevated, increasing financial risk.
Bear Case : TXG
The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
TEM profiles as a hypergrowth stock while TXG is a turnaround play — different risk/reward profiles.
TEM carries more volatility with a beta of 3.46 — expect wider price swings.
TEM is growing revenue faster at 36.1% — sustainability is the question.
TXG generates stronger free cash flow (25M), providing more financial flexibility.
Bottom Line
TEM scores higher overall (31/100 vs 20/100) and 36.1% revenue growth. TXG offers better value entry with a 68.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Tempus AI, Inc. Class A Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.
Visit Website →10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?